20-F: Tianan Technology Group Ltd. Reports Fiscal Year 2023 Results, Navigating Business Model Shift Amidst Going Concern Uncertainty

Tianan Technology Group Ltd. reports a shift in business model towards graphene-based health therapy amidst financial challenges and expresses substantial doubt about its ability to continue as a going concern.

Summary

• Tianan Technology Group Ltd., a British Virgin Islands corporation, released its Form 20-F filing for the fiscal year ended December 31, 2023.
• The company is transitioning its business model from power control systems to graphene-based health therapy products.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern due to accumulated deficits and negative working capital.
• The company reported a net loss of $250,009 for 2023, compared to a net loss of $280,517 for 2022.
• Revenues increased by 26% to $246,619 in 2023, driven by increased sales from the new graphene product line.
• The company is seeking additional funding through private placements and related party support.
• The company faces risks related to its financial condition, reliance on a limited number of major customers, and the complex regulatory environment in China.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue increased and losses decreased, the auditor's going concern warning and identified material weaknesses in internal control over financial reporting are significant concerns.

Positives

• Revenue increased by 26% to $246,619 in 2023, driven by the new graphene product line.
• The company reported a net loss of $250,009 for 2023, an improvement from the $280,517 loss in 2022.
• Gross profit increased by 26.2% to $66,681 for the fiscal year ended December 31, 2023.
• The company is actively embracing marketplace changes and shifting its business model to a differentiated and new business field.
• The company is seeking other suppliers to extend its product portfolios and reduce the supply chain risks.

Negatives

• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company has incurred an accumulated deficit of $1,064,348 as of December 31, 2023.
• The company has a negative working capital of $543,964 as of December 31, 2023.
• The company relies on a limited number of major customers for a significant portion of its revenues.
• The company identified material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on raising capital and achieving profitable operations.
• The company faces risks related to defects, errors, or disruptions to its products and services.
• The company's reliance on a limited number of major customers could negatively impact revenues if those customers reduce or cease their use of the company's products.
• The company may face increased competition from new and existing firms with greater capital resources.
• The company may incur material product liability claims.
• Changes in China's economic, political, or social conditions could have a material adverse effect on the company's business and operations.
• Uncertainties with respect to the PRC legal system could adversely affect the company.
• Governmental control of currency conversion may limit the company's ability to utilize its revenues effectively.
• The company may rely on dividends and other distributions on equity paid by its PRC subsidiary, and any limitation on the ability of the subsidiary to make payments could have a material adverse effect.
• Fluctuations in exchange rates could have a material and adverse effect on the company's results of operations and the value of your investment.
• Certain PRC regulations may make it more difficult for the company to pursue growth through acquisitions.
• If the company is classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to the company and its non-PRC shareholders.
• Uncertainties with respect to the PRC legal system could limit the legal protections available to you and us.
• If the Chinese government chooses to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers, such action could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.
• Certain existing shareholders have substantial influence over our company and their interests may not be aligned with the interests of our other shareholders.
• If securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations regarding our Shares, the market price for our Shares and trading volume could decline.
• The sale or availability for sale of substantial amounts of our Shares could adversely affect their market price.
• Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of our Ordinary Shares for return on your investment.
• We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions applicable to United States domestic public companies.
• As a foreign private issuer, we are permitted to, and we will, rely on exemptions from certain Nasdaq Stock Exchange corporate governance standards applicable to domestic U.S. issuers. This may afford less protection to holders of our shares.
• If we fail to establish and maintain proper internal financial reporting controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.

Future Outlook

The company anticipates that its current liquidity is not sufficient to meet its obligations and may need to raise additional capital to fund its operating expenses, pay its obligations, and grow its Company in the future.

Industry Context

The company is shifting its focus to the graphene-based health therapy industry, which is experiencing growth and is projected to continue to increase at a compound annual growth rate of nearly 10%, reaching approximately 64.2 trillion yuan by 2025.

Comparison to Industry Standards

• The global graphene market size was valued at $175.9 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 46.6% from 2023 to 2030.
• Key players in the graphene market include Haydale Graphene Industries PLC, Graphensic AB, and Directa Plus.
• Asia Pacific was the largest market with a revenue of $67.8 million in 2022 and is the fastest-growing region with a projected CAGR of 51.0% over the forecast period.
• China is expected to emerge as a prominent market for graphene with a CAGR of 60.9% over the forecast period in terms of volume.

Related Party Transactions

• During the years ended December 31, 2023 and 2022, the Company sold healthcare products of in the amount of $64,035 and $32,342 to one of its related parties, Suzhou Xinjianlin Health Management Co., Ltd. (Xinjianlin ).
• During the years ended December 31, 2023 and 2022, the Company borrowed an aggregate of $130,943 and $121,501 from Mr. Heng Fei Yang, and repaid $78,281 and $355,517, respectively.

Stakeholder Impact

• Shareholders face uncertainty due to the company's going concern status and potential dilution from future capital raises.
• Employees face uncertainty due to the company's financial challenges and potential restructuring.
• Customers may be impacted by the company's ability to maintain operations and provide products and services.
• Suppliers may be impacted by the company's ability to pay for goods and services.

Next Steps

• The company intends to continue to fund its business by way of private placements and financing supports from related parties as may be required.
• The company is pursuing a restructuring initiative that it hopes can extend its cash runway until its operating cash flows increase.
• The company is also pursuing additional potential financing initiatives such as strategic collaborations and marketing, distribution arrangements, business and asset divestitures and / or grant funding, among other things.

Key Dates

Keywords

graphene, health therapy, financial results, going concern, business model, China, revenue, net loss, Tianan Technology Group, financial statements